8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): April 1, 2010

ULURU Inc.

(Exact Name of Registrant as Specified in its Charter)

Nevada	000-49670	41-2118656
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

4452 Beltway Drive

Addison, Texas 75001

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (214) 905-5145

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers

Effective April 1, 2010, the Board of Directors of ULURU Inc. (the “Company”) appointed Dr. Jeffrey A. Stone to serve as a director of the Company.

Dr. Stone, age 53, is currently President of Wound Care Consultants.  He is a past president Texas Affiliate of the American Diabetes Association.  Dr. Stone received his medical degree from the College of Osteopathic Medicine of the Pacific and a Master of Public Health from Harvard University.  He completed a residency in aerospace medicine and a fellowship in hyperbaric medicine and wound care at the U.S. Air Force School of Aerospace Medicine at Brooks Air Force Base.  He is certified in hyperbaric medicine and board certified in aerospace medicine.  He is a Diplomate of the American Academy of Wound Care Management and a Certified Wound Specialist having been active in the wound field for over 20 years.

Dr. Stone will serve on the Company’s Audit, Compensation, and Nominating and Corporate Governance Committees.  In connection with his appointment to the Board, Dr. Stone was granted an option to purchase 50,000 shares of common stock at an exercise price of $0.17, the closing price of the Company’s common stock on April 1, 2010.

Item 9.01	Financial Statements and Exhibits
(d)	Exhibits
Exhibit No.	Description
99.1	Press Release dated April 5, 2010

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ULURU Inc.
Date: April 5, 2010	By:	/s/ Terrance K. Wallberg
		Terrance K. Wallberg
		Vice President and Chief Financial Officer

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press Release dated April 5, 2010

EX-99.1

ULURU NEWS

Contact: Company

Renaat Van den Hooff

President & CEO

Terry K. Wallberg

Vice President & CFO

(214) 905-5145

ULURU INC.

ANNOUNCES THE APPOINTMENT OF DR. JEFFREY A. STONE

TO THE BOARD OF DIRECTORS

Addison, Texas, April 5, 2010; ULURU Inc. (NYSE AMEX: ULU) today announced that Jeffrey A. Stone, D.O., M.P.H., FCCWS has been appointed to serve on the Company’s Board of Directors.

Dr. Stone is currently President of Wound Care Consultants.  He is a past president Texas Affiliate of the American Diabetes Association.  Dr. Stone received his medical degree from the College of Osteopathic Medicine of the Pacific and a Master of Public Health from Harvard University.  He completed a residency in aerospace medicine and a fellowship in hyperbaric medicine and wound care at the U.S. Air Force School of Aerospace Medicine at Brooks Air Force Base.  He is certified in hyperbaric medicine and board certified in aerospace medicine.  He is a Diplomate of the American Academy of Wound Care Management and a Certified Wound Specialist having been active in the wound field for over 20 years.

Dr. Stone not only has extensive experience in the treatment of chronic wounds but has also been involved in both Medicare and Medicaid in Texas, on the editorial advisory board and as a reviewer for wound care journals and with a health insurance company.  He has also held the position of medical director of the wound care programs at numerous hospitals and long-term acute care facilities throughout the Dallas metroplex.

“I am excited to be joining the Board at ULURU and believe that the Company’s innovative array of products and technologies will help improve outcomes in patients with chronic non-healing wounds” said Dr. Stone.

Commenting on the appointment, Renaat Van den Hooff, President and CEO stated, “We are pleased to have a recognized medical practitioner with vast wound care experience such as Dr. Stone joining our Board.  His extensive clinical experience directing wound care programs and managing wound care clinics will be invaluable as we continue commercializing AltrazealTM.  We very much look forward to his contributions to help us build a successful wound care business”.

About ULURU Inc.:

ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex™ Aggregate technology and OraDisc™ transmucosal delivery system. For further information about ULURU Inc., please visit our website at www.uluruinc.com.  For further information about Altrazeal™, please visit our website at www.altrazeal.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including but not limited to statements made relating to the value of our products in the marketplace, our ability to develop and market our technologies and commercialization of products in the marketplace. These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2009, and other reports filed by us with the Securities and Exchange Commission.